| Literature DB >> 35712474 |
Jing-Yu Benjamin Tan1, Jianxia Zhai2, Tao Wang3, Hong-Juan Zhou4, Isabella Zhao3,5, Xian-Liang Liu3.
Abstract
Background: A growing number of clinical practice guidelines (CPGs) regarding non-pharmacological interventions for breast cancer survivors are available. However, given the limitations in guideline development methodologies and inconsistent recommendations, it remains uncertain how best to design and implement non-pharmacological strategies to tailor interventions for breast cancer survivors with varied health conditions, healthcare needs, and preferences. Aim: To critically appraise and summarise available non-pharmacological interventions for symptom management and health promotion that can be self-managed by breast cancer survivors based on the recommendations of the CPGs.Entities:
Keywords: breast cancer; clinical practice guidelines; content analysis; non-pharmacological interventions; self-management
Year: 2022 PMID: 35712474 PMCID: PMC9195587 DOI: 10.3389/fonc.2022.866284
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
Search strategy in PubMed.
| #1 | breast neoplasm [MeSH Terms] |
| #2 | (((((((((((((Breast Neoplasm*[Title/Abstract]) OR (Breast tumor*[Title/Abstract])) OR (Breast cancer*[Title/Abstract])) OR (Breast carcinoma*[Title/Abstract])) OR (Mammary cancer*[Title/Abstract])) OR (Mammary carcinoma*[Title/Abstract])) OR (Mammary neoplasm*[Title/Abstract])) OR (Mammary tumor*[Title/Abstract])) OR (Malignant neoplasm of breast[Title/Abstract])) OR (Breast malignant neoplasm*[Title/Abstract]))) OR (Malignant tumor of breast[Title/Abstract])) OR (Breast malignant tumor*[Title/Abstract])) OR (Cancer of breast[Title/Abstract]) |
| #3 | #1 OR #2 |
| #4 | guideline [MeSH Terms] |
| #5 | ((((((((((guideline[Publication Type]) OR (Practice Guideline[Publication Type]))) OR (guideline*[Title/Abstract])) OR (Best Practice*[Title/Abstract])) OR (Recommendation*[Title/Abstract])) OR (Consensus*[Title/Abstract])) OR (Experts Opinion*[Title/Abstract]) |
| #6 | #4 OR #5 |
| #7 | #3 AND #6 |
Figure 1PRISMA flow diagram of study selection. Adapted from: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372.
Characteristics of the included clinical practice guidelines.
| Name of CPG | Abbreviated Name | Developer | Year Published/Updated | Publication in a Journal | Newly Developed | Continent/country | Evidence Analysis | Quality Tool Referral |
|---|---|---|---|---|---|---|---|---|
| Advanced breast cancer: diagnosis and treatment (CG81) ( | NICE (CG81) | NICE | 2017 | Not published | No | UK | Systematic review; consensus method among experts, including patient/carer | AGREE II |
| Early and locally advanced breast cancer: diagnosis and management (NG101) ( | NICE (NG101) | NICE | 2018 | Not published | No | UK | Systematic review; consensus method among experts, including patient/carer | AGREE II |
| Recommendations for the follow-up care of female breast cancer survivors ( | Barnadas, Algara ( | SEOM, SEMERGEN, SEMFYC, SEMG, SEGO, SEOR, SESPM, SEC | 2018 | Clinical and Translational Oncology | Yes | Spain | Consensus method, not specified | Not reported |
| Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019 ( | St. Gallen International Consensus | St. Gallen | 2019 | Annals of Oncology | No | Europe | Nominal group technique | Not reported |
| SEOM clinical guidelines in early-stage breast cancer ( | SEOM guideline | SEOM | 2018 | Clinical and Translational Oncology | No | Spain | Consensus method, not specified | Not reported |
| Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up ( | ESMO (EBC) | ESMO | 2019 | Annals of Oncology | No | Europe | Review | Not reported |
| ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4) ( | ESO-ESMO (BCY4) | ESO, ESMO | 2020 | Annals of Oncology | No | Europe | Consensus method, expert panel review, | Not reported |
| 5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5) ( | ESO-ESMO (ABC 5) | ESO, ESMO | 2020 | Annals of Oncology | No | Europe | Nominal group technique, | Not reported |
| Interventions for Breast Cancer-Related Lymphedema: Clinical Practice Guideline from the Academy of Oncologic Physical | APTA guideline | APTA | 2020 | Physical Therapy | Yes | US | Review | Not reported |
| Clinical Practice Guidelines on the Evidence-based Use of Integrative Therapies During and After Breast Cancer Treatment ( | SIO guideline | SIO | 2017 | CA: A Cancer Journal for Clinicians | No | US | Systematic review | Not reported |
| ONS Guidelines™ for Cancer | ONS guideline | ONS | 2020 | Oncology Nursing Forum | Yes | US | Systematic review, consensus method among experts, | Not reported |
| Practice guidelines for psychological interventions in the rehabilitation of patients with oncological disease (breast, prostate, or colorectal cancer) ( | Reese, Weis ( | University of Freiburg | 2016 | Psycho‐Oncology | Yes | Germany | Review, consensus method (expert panel), | Not reported |
| American Cancer Society (ACS)/American Society of Clinical Oncology (ASCO) Breast Cancer Survivorship Care Guideline ( | ACS-ASCO guideline | ACS, ASCO | 2016 | CA: A Cancer Journal for Clinicians | Yes | USA | Systematic review, consensus method (expert workshop), including a patient | Not reported |
| Follow-up after treatment for breast cancer: Practical guide to survivorship care for family physicians ( | Sisler, Chaput ( | College of Family Physicians | 2016 | Canadian Family Physician | Yes | Canada | Review | Not reported |
NICE, National Institute for Health and Care Excellence; UK, United Kingdom; AGREE II, Appraisal of Guidelines for Research and Evaluation, second edition; SEOM, Sociodad Española de Oncolgía Médica; ESMO, European Society for Medical Oncology; EBC, early breast cancer; ESO, European School of Oncology; ABC, advanced breast cancer; APTA, American Physical Therapy Association; US, United States; SIO=Society of Interventional Oncology; ONS, Oncology Nursing Society.
Scores of the domains and overall assessment of the guidelines according to the AGREE II instrument.
| Title of Guideline | Domains (%) | Overall Quality | Degree of Recommendation | ICC | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Scope and Purpose | Stakeholder Involvement | Rigor of Development | Clarity and Presentation | Applicability | Editorial Independence | Average | ||||
| NICE (CG81) ( | 100 | 100 | 92.2 | 88.9 | 91.7 | 89.6 | 93.73 | High | R | 0.995 |
| NICE (NG101) ( | 100 | 100 | 92.7 | 88.9 | 91.7 | 89.6 | 93.82 | High | R | 0.993 |
| Barnadas, Algara ( | 70.8 | 25.0 | 50.0 | 31.9 | 12.5 | 70.8 | 43.50 | Low | NR | 0.989 |
| St. Gallen International | 69.4 | 61.1 | 19.8 | 38.8 | 19.7 | 62.5 | 45.22 | Moderate | RM | 0.980 |
| ESMO (EBC) 2019 | 73.6 | 66.7 | 44.8 | 41.7 | 45.8 | 66.7 | 56.55 | Moderate | RM | 0.970 |
| ESO-ESMO (ABC5) 2020 ( | 87.5 | 70.8 | 42.7 | 79.2 | 55.2 | 68.8 | 67.37 | Moderate | RM | 0.956 |
| ESO-ESMO (BCY4) 2020 ( | 83.3 | 72.2 | 63.5 | 69.4 | 53.1 | 68.8 | 68.38 | Moderate | RM | 0.973 |
| APTA guideline ( | 95.8 | 68.1 | 79.2 | 81.9 | 30.2 | 68.8 | 70.67 | Moderate | RM | 0.993 |
| SEOM 2018 ( | 69.4 | 36.1 | 18.2 | 47.2 | 12.5 | 33.3 | 36.12 | Low | NR | 0.986 |
| SIO guideline ( | 97.2 | 76.4 | 89.6 | 97.2 | 77.1 | 91.7 | 88.20 | High | R | 0.983 |
| ONS guideline ( | 88.9 | 88.9 | 77.1 | 83.3 | 77.1 | 91.7 | 84.50 | High | R | 0.991 |
| Reese, Weis ( | 83.3 | 83.3 | 53.1 | 44.4 | 49.0 | 66.7 | 63.30 | Moderate | RM | 0.985 |
| ACS-ASCO guideline | 93.1 | 93.1 | 98.0 | 87.5 | 83.3 | 91.7 | 91.12 | High | R | 0.992 |
| Sisler, Chaput ( | 72.2 | 58.3 | 51.6 | 45.8 | 15.6 | 50.0 | 48.92 | Moderate | RM | 0.994 |
|
| 84.61 | 71.43 | 62.32 | 66.15 | 51.04 | 72.19 | 67.96 | – | – | 0.980 |
ICC, intraclass correlation coefficient; NICE, National Institute for Health and Care Excellence; R, recommended; NR, not recommended; RM, recommended with modifications; ESMO, European Society for Medical Oncology; EBC, early breast cancer; ESO, European School of Oncology; ABC, advanced breast cancer; APTA, American Physical Therapy Association; SEOM, bSociodad Española de Oncolgía Médica; SIO, Society of Interventional Oncology; ONS, Oncology Nursing Society; ACS, American Cancer Society; ASCO, American Society of Clinical Oncology.
Non-pharmacological interventions and therapies recommended by the included clinical practice guidelines.
| Clinical Outcomes | Recommended Non-pharmacological Interventions/Therapies | Guidelines | Grading System Used |
|---|---|---|---|
|
|
| ESO-ESMO (ABC5) 2020 | Infectious Diseases Society of America–United States Public Health Service Grading System |
|
| ESO-ESMO (ABC5) 2020 | Infectious Diseases Society of America–United States Public Health Service Grading System | |
|
| ESO-ESMO (ABC5) 2020 | Infectious Diseases Society of America–United States Public Health Service Grading System | |
|
| SIO 2017 | Modified version of the US Preventive Services Task Force Grading System | |
|
| SIO 2017 | Modified version of the US Preventive Services Task Force Grading System | |
|
| SIO 2017 | Modified version of the US Preventive Services Task Force Grading System | |
|
| SIO 2017 | Modified version of the US Preventive Services Task Force Grading System | |
|
| SIO 2017 | Modified version of the US Preventive Services Task Force Grading System | |
|
| SIO 2017 | Modified version of the US Preventive Services Task Force grading system | |
|
|
| SIO 2017 | Modified version of the US Preventive Services Task Force Grading System |
|
| SIO 2017 | Modified version of the US Preventive Services Task Force Grading System | |
|
|
| NICE 2017 | SIGN criteria |
|
| ESO-ESMO (ABC5) 2020 | Infectious Diseases Society of America–United States Public Health Service Grading System | |
|
| ESO-ESMO (ABC5) 2020 | Infectious Diseases Society of America–United States Public Health Service Grading System | |
|
| ESO-ESMO (ABC5) 2020 | Infectious Diseases Society of America–United States Public Health Service Grading System | |
|
| ESO-ESMO (ABC5) 2020 | Infectious Diseases Society of America–United States Public Health Service Grading System | |
|
| ACS-ASCO 2016 | Not classified | |
|
| Sisler et al. ( | Not classified | |
|
| SIO 2017 | Modified version of the US Preventive Services Task Force Grading System | |
|
| SIO 2017 | Modified version of the US Preventive Services Task Force Grading System | |
|
| Sisler et al. ( | Not specified | |
|
|
| ESMO (EBC) | Infectious Diseases Society of America–United States Public Health Service Grading System |
|
| ACS-ASCO 2016 | Not classified | |
|
| Davies et al. ( | Oxford Centre for Evidence-Based Medicine–levels of evidence | |
|
| ACS-ASCO 2016 | Not classified | |
|
| Sisler et al. ( | Not classified | |
|
|
| SIO 2017 | Modified version of the US Preventive Services Task Force Grading System |
|
| SIO 2017 | Modified version of the US Preventive Services Task Force Grading System | |
|
| SIO 2017 | Modified version of the US Preventive Services Task Force Grading System | |
|
| Sisler et al. ( | Not classified | |
|
| Sisler et al. ( | Not classified | |
|
| ACS-ASCO 2016 | Not classified | |
|
|
| ACS-ASCO 2016 | Not classified |
|
|
| ESO-ESMO (ABC5) 2020 | Infectious Diseases Society of America–United States Public Health Service Grading System |
|
| ESO-ESMO (ABC5) 2020 | Infectious Diseases Society of America–United States Public Health Service Grading System | |
|
| ESO-ESMO (ABC5) 2020 | Infectious Diseases Society of America–United States Public Health Service Grading System | |
|
| ESO-ESMO (ABC5) 2020 | Infectious Diseases Society of America–United States Public Health Service Grading System | |
|
| SIO 2017 | Modified version of the US Preventive Services Task Force Grading System | |
|
| SIO 2017 | Modified version of the US Preventive Services Task Force Grading System | |
|
| SIO 2017 | Modified version of the US Preventive Services Task Force Grading System | |
|
| SIO 2017 | Modified version of the US Preventive Services Task Force Grading System | |
|
|
| SIO 2017 | Modified version of the US Preventive Services Task Force Grading System |
|
| Reese et al. ( | No grading system | |
|
|
| ONS 2020 | GRADE |
|
|
| NICE 2018 | SIGN criteria |
|
| NICE 2018 | SIGN criteria | |
|
| St. Gallen 2019 | Not classified | |
|
| SEOM 2018 | Infectious Diseases Society of America–United States Public Health Service Grading System | |
|
| SEOM 2018 | Infectious Diseases Society of America–United States Public Health Service Grading System |
MBSR, mindfulness-based stress reduction; NR, not reported; LoE, level of evidence; GoR, grade of recommendation; SoE, strength of evidence; ESO, European School of Oncology; ESMO, European Society for Medical Oncology; ABC, advanced breast cancer; SIO, Society of Interventional Oncology; US, United States; RCT, randomised controlled trial; NICE, National Institute for Health and Care Excellence; SIGN, Scottish Intercollegiate Guidelines Network; ACS, American Cancer Society; ASCO, American Society of Clinical Oncology; ONS, Oncology Nursing Society; GRADE, Grading of Recommendations Assessment, Development, and Evaluation; SEOM, Sociodad Española de Oncolgía Médica.
Health promotion for breast cancer survivors per the included clinical practice guidelines.
| Recommendations | Guidelines | Grading System Used | |
|---|---|---|---|
|
|
| ACS-ASCO 2016 | Not classified |
|
|
| ACS-ASCO 2016 | Not classified |
|
| Barnadas et al. ( | No grading system | |
|
| Sisler et al. ( | Not classified | |
|
| ESMO (EBC) | Infectious Diseases Society of America–United States Public Health Service Grading System | |
|
| Reese et al. ( | No grading system | |
|
|
| Reese et al. ( | No grading system |
|
| ESMO (EBC) | Infectious Diseases Society of America–United States Public Health Service Grading System | |
|
| ACS-ASCO 2016 | Not classified | |
|
| Barnadas et al. ( | No grading system | |
|
| Sisler et al. ( | Not classified | |
|
|
| Barnadas et al. ( | No grading system |
|
| ACS-ASCO 2016 | Not classified | |
|
| Sisler et al. ( | Not classified | |
|
|
| ACS-ASCO 2016 | Not classified |
|
| Sisler et al. ( | Not classified |
NR, not reported; LoE, level of evidence; GoR, grade of recommendation; SoE, stremgth of evidence; ACS, American Cancer Society; ASCO, American Society of Clinical Oncology; ESMO, European Society for Medical Oncology EBC, early breast cancer.